title: Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?
abstract: In the last 15 years, antiretroviral therapy (ART) has been the most globally impactful life-saving development of medical research. Antiretrovirals (ARVs) are used with great success for both the treatment and prevention of HIV infection. Despite these remarkable advances, this epidemic grows relentlessly worldwide. Over 2.1 million new infections occur each year, two-thirds in women and 240,000 in children. The widespread elimination of HIV will require the development of new, more potent prevention tools. Such efforts are imperative on a global scale. However, it must also be recognised that true containment of the epidemic requires the development and widespread implementation of a scientific advancement that has eluded us to date--a highly effective vaccine. Striving for such medical advances is what is required to achieve the end of AIDS.
authors.affiliation: South African Medical Research Council, Cape Town, South Africa.|Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
authors.forename: Glenda E
authors.initials: GE
authors.lastname: Gray
authors.affiliation: Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
authors.forename: Fatima
authors.initials: F
authors.lastname: Laher
authors.affiliation: South African Medical Research Council, Cape Town, South Africa.|School of Public Health, University of Western Cape, Bellville, South Africa.|School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
authors.forename: Tanya
authors.initials: T
authors.lastname: Doherty
authors.affiliation: Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.|Mailman School of Public Health, Columbia University, New York City, New York, United States of America.
authors.forename: Salim
authors.initials: S
authors.lastname: Abdool Karim
authors.affiliation: Columbia University Medical Center, New York City, New York, United States of America.
authors.forename: Scott
authors.initials: S
authors.lastname: Hammer
authors.affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Bethesda, Maryland, United States of America.
authors.forename: John
authors.initials: J
authors.lastname: Mascola
authors.affiliation: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.|The International AIDS Society, Geneva, Switzerland.
authors.forename: Chris
authors.initials: C
authors.lastname: Beyrer
authors.affiliation: HIV Vaccine Trials Network, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors.forename: Larry
authors.initials: L
authors.lastname: Corey
mesh_terms: D016915:AIDS Vaccines; D000891:Anti-Infective Agents, Local; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D057134:Antibodies, Neutralizing; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D010372:Pediatrics
chemical_list: D016915:AIDS Vaccines; D000891:Anti-Infective Agents, Local; D044966:Anti-Retroviral Agents; D057134:Antibodies, Neutralizing